the pharmacokinetics, logged
PT-141 Half-Life, Onset, and Duration in the Research
A short half-life of roughly 2.7 hours, a fast Tmax, and an as-needed window — the numbers stated flatly and sourced.
The short version
The PT-141 half life is short. After a subcutaneous (injected just under the skin) dose, the terminal half-life is about 2.7 hours per the US label [11]. It reaches peak blood levels fast — within about half an hour to an hour — and clears over a few hours, which is why it is used as needed rather than daily [11]. Older intranasal research reported a slightly shorter half-life around 1.85-2.09 hours [6]. The body removes most of it through the kidneys [11]. The numbers below are reported as findings, not as a schedule for anyone to follow.
What is the half-life of PT-141?
The terminal half-life of PT-141 is approximately 2.7 hours after subcutaneous administration, with a range of 1.9-4.0 hours, per the US prescribing information for bremelanotide [11]. Half-life is the time it takes for the amount in the blood to fall by half; after a few half-lives, most of the drug is gone. Early intranasal studies in men reported a shorter terminal half-life of 1.85-2.09 hours [6].
The difference reflects route and formulation, not a different molecule. The approved subcutaneous figure (~2.7 h) is the authoritative one; the intranasal range belongs to the discontinued early formulation [6][11]. Either way, the number tells you this is a short-acting compound, not one that builds up over days — which is exactly why the label frames it as an as-needed drug rather than a daily one [11].
Onset: how long PT-141 takes to work
Onset is fast and measured two ways. The label directs dosing at least 45 minutes before anticipated activity, and the median Tmax — the time to peak blood concentration — is roughly 0.5-1.0 hours after subcutaneous injection [11]. Tmax is simply how long after a dose the drug reaches its highest level in the blood.
The early male erectile work put a number on the pharmacodynamic onset: intranasal PT-141 produced a first erectile response at about 30 minutes in responsive men [6]. That is an off-label, early-phase finding, not an approved use, but it is consistent with the pharmacokinetics — peak exposure and first measurable effect both land within the first hour [6][11]. The 45-minute pre-dosing instruction in the label reflects that fast-but-not-instant onset [11].
How long PT-141 lasts
Duration follows the half-life. With a terminal half-life near 2.7 hours, plasma levels fall over several hours after a subcutaneous dose, so the drug is used as needed rather than on a daily schedule [11]. In the mechanistic fMRI study, MC4R agonism raised sexual desire for up to 24 hours — a downstream, central effect that outlasts the plasma curve, not a measure of drug persistence [5].
The distinction matters: how long the molecule lingers (a few hours) is not the same as how long a behavioral effect is detectable (reported up to a day in one study) [5][11].
Clearance: how long PT-141 stays in your system
Clearance is renal-dominant. Per the label, bremelanotide has a volume of distribution of about 25.0 L, clearance about 6.5 L/hr, and roughly 21% serum protein binding [11]. Volume of distribution is a rough measure of how widely a drug spreads through the body's tissues; clearance is how fast the body removes it. It is metabolized by hydrolysis of the cyclic-peptide amide bonds and by peptidase digestion — the body breaks the peptide ring apart and chews up the fragments [11].
In a radiolabeled study, excretion was 64.8% renal (through the kidneys, into urine) and 22.8% fecal [11]. Given the ~2.7 h half-life, the bulk of the drug is cleared over several hours rather than days [11]. The renal-heavy route is one reason kidney function is a relevant consideration in the label's pharmacology, though specific dosing in renal impairment is a clinical matter outside this site's scope.
Does PT-141 nasal spray work?
The intranasal route showed a real but inconsistent effect. Early intranasal studies in men reported a dose-dependent erectile response above 7 mg [6]. But the intranasal formulation was discontinued due to pharmacokinetic variability, and development moved to the subcutaneous route, which is the approved one [6][11]. So the nasal spray "worked" in early trials yet was not the form that reached approval — an early-phase, off-label finding, not an approved use.
The pharmacokinetics in one view
Put together, the PT-141 pharmacokinetic profile is the profile of a short-acting, as-needed drug. Subcutaneous dosing reaches peak blood levels in about 0.5-1.0 hours (Tmax), carries a terminal half-life near 2.7 hours, and clears mostly through the kidneys, with renal/fecal excretion around 64.8%/22.8% [11]. The label's instruction to dose at least 45 minutes ahead and no more than once per 24 hours follows directly from those numbers [11].
What the plasma curve does not capture is the downstream effect. The fMRI study reported a central desire effect lasting up to 24 hours — longer than the drug itself lingers — because the behavioral consequence outlasts the molecule [5]. Pharmacokinetics describe the drug's stay in the body; pharmacodynamics describe what it does while and after it is there, and for PT-141 those two timelines are not the same [5][11].